Licensing News: Breaking Licensing News, Comments and Articles. - Page: 2

Edison Investment - e-Therapeutics Results update - Progress in development and discovery

e-Therapeutics has provided a comprehensive update of its development pipeline. ETS2101, for various solid tumours, is the major focus and is progressing through Phase I trials with encouraging early results. A proof-of concept study for the antidepressant ETS6103 is due to start shortly, with results expected in H214. The first new drug candidate to emerge from the newly bolstered discovery pla...

Edison Investment - Algeta - Investment summary - FDA go for Xofigo

The FDA’s approval of Xofigo for metastatic prostate cancer will trigger a €50m milestone to Algeta from partner Bayer in Q213. The broad label, early approval and premium pricing could result in upgrades to 2013 consensus sales forecasts. Despite this, we anticipate a measured commercial launch initially targeting US sites involved in the early access programme (EAP). Algeta’s...

Columbia University licenses 3D segmentation software to Varian

Columbia University has signed a licensing agreement with Varian Medical Systems for novel imaging software that facilitates 3D segmentation, the process by which anatomical structures in medical images are distinguished from one another—an importa...

Global Vision Text Comparison Software Docu-Proof Recognized by the EMA for Regulatory Submissions

MONTREAL, May 21, 2013 /PRNewswire/ -- Global Vision, the industry leader in the development of automated proofreading solutions, today announced that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency (EMA) for pharmaceutical companies using parallel distribution methods of medicinal products. For pharmaceutical companie...

Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™

Aradigm’s Proprietary Inhaled Ciprofloxacin Formulation is a Potential New Therapy for Patients with Severe Respiratory Disease Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) (“Grifols”) and Aradigm Corporation (OTC BB:ARDM.OB) (“Aradigm”) today announced the signing of an exclusive, worldwide license for Aradigm’s proprietary formulati...

Grifols Taking Aradigm Stake in Up To $116M Licensing Deal

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols, S.A. and Aradigm Corporation today announced the signing of an exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including...

Global Vision's Text Comparison Software Docu-Proof Recognized by the EMA for Regulatory Submissions

With Docu-Proof, Annual Update and Change Notification Fees Reduced By 50% Montreal, CANADA (PRWEB) May 21, 2013 Global Vision, the industry leader in the development of automated proofreading solutions, today announced that Docu-Proof has met compliance requirements as a text comparison software solution by the European Medicines Agency (EMA) for pharmaceutical companies using parallel distribut...

Stockholm Business Region: Exclusive Showcase at BioEquity Europe 2013 in Stockholm: Meet Stockholm’s Most Promising Life Science Companies

The 14th annual BioEquity Europe is being held in Stockholm tomorrow May 22nd 2013. The conference offers a unique possibility to meet companies listed on Stockholm-Uppsala Life Science Investment Hotlist during an exclusive showcase. The hotlist features carefully selected, investment-ready Stockholm-Uppsala based companies on the cutting edge of...

Pharmalicensing and Bionow sign strategic marketing and member benefit agreement

York, UK & Manchester, UK - May 20th, 2013 – Pharmalicensing, a division of IP Technology Exchange, Inc, today announced it has agreed a partnership with Bionow, the membership company representing the interests of life science organisation...

Safilo, Essilor in 10-year licensing deal

MILAN, May 21 (Reuters) - Italy's eyewear maker Safilo said on Tuesday it had agreed a 10-year licensing deal with France's Essilor, the world's biggest maker of corrective eye lenses.

Perry Ellis International Announces Licensing Agreement With Delta Galil for Original Penguin by Munsingwear Sleepwear and Underwear

MIAMI, May 21, 2013 (GLOBE NEWSWIRE) -- Perry Ellis International (PEI) (Nasdaq:PERY) announced today that it has entered into a license agreement with Delta Galil Industries USA, granting rights for Original Penguin by Munsingwear men's underwear and sleepwear for the U.S. and Canada. Original Penguin, one of the most recognizable brands in the PEI power portfolio, is known for its modern vintag...

Adeptia Announces New Release of Enterprise Business Integration Solution

Industry Leader Advances Next-generation Integration Solution with Key Performance, Usability and Enterprise-class Enhancements Chicago, IL (PRWEB) May 20, 2013 Adeptia Inc., a leading provider of innovative cloud and on-premise business process integration solutions, today announced the availability of version 6.0 of its next-generation integration solution. Version 6.0 is the only process-cent...

Vote Yes on F

LOS ANGELES, May 20, 2013 /PRNewswire/ -- On May 21 join Angelenos for Safe Access -  a coalition of business, collectives, doctors and patients - in voting Yes on F and No on D. Proposition D is a fraud that doesn't work.  Proposition D doesn't protect minors, patients or the public. Ordinance F is the solution to create sustainable and healthy rules that would - regulate medical...

Viewpoints: Sebelius' 'Ethical Line'; As Tricky Phase Of Health Law Approaches, Concerns About Exchanges Opening On Time

The Washington Post: Kathleen Sebelius Dances On An Ethical Line One of the biggest questions hanging over the health-care system is how many young Americans will sign up for coverage once the Affordable Care Act begins to phase in this October. If too few buy insurance on the markets that the government is creating, insurance companies would be stuck covering primarily the old and the sick. They...

Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth

NEW YORK, LONDON, BERLIN and PARIS, May 20, 2013 /PRNewswire/ -- Arthroscopy Devices Market to 2018 - Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Future Growth" looks at the market landscape, competitive landscape, and market trends for the six arthroscopy device market segments: arthroscopes, arthroscopy shavers, arthroscopy Fluid Management...

eFFECTOR Therapeutics Raises $45 Million in Series A Financing

SAN DIEGO, May 20, 2013 /PRNewswire/ -- eFFECTOR Therapeutics, a newly established biopharmaceutical company, today announced the completion of a $45 million Series A financing.  eFFECTOR is focused on inventing and developing small molecule drugs to selectively regulate protein synthesis, also known as translation, with an initial emphasis on cancer.  Series A investors include U.S. Ven...

Partnering with Pfizer: Collaborating to give hope

Pfizer is a top pharma company active in partnering, licensing and M&A in pharmaceuticals. Pfizer’s tag lines for partnering include: Partner-driven Join us in advancing our vision of a healthier world Partners welcome Advancing medical breakthroughs Collaborating to give hope Pfizer believes that working together is critical to harnessing innovative science. Pfizer seek strong, long-term...

Pfizer partnering activity 2005-2013

Pfizer announced over 410 partnering / licensing deals since 2005, with 59 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology, infectives, central nervous system, cardiovascular, metabolic, psychiatric and ophthalmic diseases. Abstracted from: Partnering Deals and Alliances with Pfizer The number of partnering, collaborative R&D and licens...

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence

In response to tenacious stress signals, such as the unscheduled activation of oncogenes, cells can mobilize tumour suppressor networks to avert the hazard of malignant transformation. A large body of evidence indicates that oncogene-induced senescen...

The 14th Annual BioEquity Europe Conference Features 96 Innovator Companies With Differentiated Products, Upcoming Milestones and Partner-Ready Assets

REDWOOD CITY, CA -- (Marketwired) -- 05/20/13 -- BioCentury, EBD Group and the Biotechnology Industry Organization (BIO) will convene the 14th Annual BioEquity Europe conference in Stockholm, Sweden on Wednesday, May 22, and Thursday, May 23, at the Sheraton Stockholm Hotel. Over 500 life science investment professionals and pharmaceutical business development and licensing executives already hav...

Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover

Rio Salon and Spa of Morro Bay offers refreshed, upscale décor and expanded spa and salon services in its newly remodeled beauty salon. http://riospaandsalon.com Morro Bay, CA (PRWEB) May 18, 2013 Rio Salon and Spa, a Morro Bay salon, has recently completed a stylish renovation that features tranquil, Eastern Asian influenced furnishings, decorative fine art and advanced specialties. From th...

Puma Biotechnology Comment on Trading Activity

Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, has been contacted by the New York Stock Exchange regarding today’s trading in the Company’s common stock. It is the Company’s policy not to comment on trading activity. About Puma Biotechnology Puma Biotechnology, Inc. is a development stage bioph...

Columbia University signs licensing agreement with Varian Medical Systems for novel imaging software

Columbia University has signed a licensing agreement with Varian Medical Systems for novel imaging software that facilitates 3-D segmentation, the process by which anatomical structures in medical images are distinguished from one another-an importan...

Tech Council of Maryland Names GlycoMimetics CEO Rachel King as 2013 Executive of the Year

GlycoMimetics, Inc. announced today that the Tech Council of Maryland (TCM) named Rachel K. King, GlycoMimetics Chief Executive Officer, as the winner of its 2013 Executive of the Year award. Ms. King was honored last night at the TCM's 25th Annual Tech Awards Celebration at the Bethesda North Marriott Hotel & Conference Center in Rockville, Mar...